Ezetimibe Tablet
Product Images NDC 50268-298

7 FDA label images from Avpak · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ezetimibe (NDC 50268-298). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Table 1)

1 (Table 1)
A data table listing adverse reactions occurring in 2% or more of patients and greater than placebo in Ezetimibe 10 mg treated patients versus placebo. It compares percentages of reactions such as upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza between placebo and Ezetimibe groups with sample sizes of 1,159 and 2,396 respectively.*
FDA Label Image

1 (Table 2)

1 (Table 2)
A table presenting adverse reactions occurring in 2% or more of Ezetimibe-treated patients co-administered with a statin versus all statins alone. It lists the percentage incidence of reactions like nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue, comparing the two groups.*
FDA Label Image

1 (Table 3)

1 (Table 3)
A table titled 'Clinically Important Drug Interactions with Ezetimibe' detailing interactions with cyclosporine, fibrates, and bile acid sequestrants. It includes sections for clinical impact and interventions related to each drug interaction with ezetimibe.*
FDA Label Image

Structure (Ezitimibe Tablets 1)

Structure (Ezitimibe Tablets 1)
Chemical structure diagram showing the molecular formula of Ezetimibe, the active ingredient in the prescription drug Ezetimibe 10 mg oral tablets by AvPAK.*
FDA Label Image

1 (Table 4)

1 (Table 4)
A data table titled 'Effect of Co-administered Drugs on Total Ezetimibe' detailing the impact of various co-administered drugs and dosing regimens on total ezetimibe levels, specifically changes in AUC and Cmax percentages. The table includes several drugs such as cyclosporine, fenofibrate, gemfibrozil, cholestyramine, and statins, with notes on study conditions and dosing details.*
FDA Label Image

1 (Table 5)

1 (Table 5)
A data table titled 'Effect of Ezetimibe Co-administration on Systemic Exposure to Other Drugs' showing co-administered drugs with their dosage regimens, corresponding Ezetimibe dosage regimens, and changes in AUC and Cmax of co-administered drugs due to Ezetimibe. It includes various drugs such as Warfarin, Digoxin, Gemfibrozil, contraceptives, several statins, and others, along with arrows indicating increase or decrease percentages in drug exposure metrics.*
FDA Label Image

1 (298 12)

1 (298 12)
Packaging label for Ezetimibe Tablets, USP 10 mg, containing 20 tablets in a unit dose format (2 x 10). The label includes the NDC 50268-298-12 and is manufactured for AvPAK, Pulaski, TN. It provides storage instructions and a barcode, along with a QR code and the AvPAK logo at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.